Welcome to our dedicated page for LAVA Therapeutics N.V. news (Ticker: LVTX), a resource for investors and traders seeking the latest updates and insights on LAVA Therapeutics N.V. stock.
LAVA Therapeutics N.V. (LVTX) news coverage on this page centers on the company’s evolution as a clinical-stage immuno-oncology developer and its corporate transition following an acquisition by XOMA Royalty Corporation. Company press releases and SEC-linked announcements describe how LAVA advanced its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers, while also undertaking restructuring measures and a strategic review that ultimately led to a tender offer and change of control.
Readers can follow updates related to LAVA’s pipeline programs, including the internal candidate LAVA‑1266 for CD123+ hematologic malignancies and partnered Phase 1 programs JNJ‑89853413 with Johnson & Johnson and PF‑08046052 with Pfizer Inc. News items detail clinical trial progress, portfolio reprioritization, and decisions to discontinue earlier programs such as LAVA‑1207 and LAVA‑051. These releases provide insight into how the company focused its resources on select assets while maintaining key collaborations.
Another major theme in LVTX news is corporate and capital structure events. LAVA announced an evaluation of strategic options, workforce reductions, closure of Netherlands operations, and a waiver of an Innovation Credit repayment obligation from the Netherlands Enterprise Agency (RVO). Subsequent news and 8‑K references document the share purchase agreement with XOMA Royalty Corporation, amendments to the offer terms, shareholder approvals at an extraordinary general meeting, and the successful tender of a large majority of outstanding shares.
For investors researching LVTX historically, this news stream provides context on both the scientific direction of LAVA’s Gammabody® platform and the sequence of events that resulted in LAVA becoming a majority-owned subsidiary of XOMA Royalty Corporation and delisting from the Nasdaq Global Select Market. Bookmark this page to access archived announcements, transaction milestones, and program updates associated with the former LVTX listing.
LAVA Therapeutics (Nasdaq: LVTX) announced it will present updated data from its ongoing Phase 1/2a clinical trial of LAVA-051 at the ASH Annual Meeting, December 10-13, 2022. This data will include safety, pharmacodynamics, and pharmacokinetics, along with first results from subcutaneous administration and updates on intravenous dosing cohorts. The lead candidate targets relapsed/refractory multiple myeloma and chronic lymphocytic leukemia. The presentation is scheduled for December 10, 2022, by Arnon P. Kater, M.D., Ph.D.
LAVA Therapeutics, a clinical-stage immuno-oncology company (Nasdaq: LVTX), has appointed Fred M. Powell as its new Chief Financial Officer effective immediately. Mr. Powell brings over 20 years of CFO experience in the biopharmaceutical sector, including significant roles in investor relations and strategic planning. Previously, he led the financial team at Antares Pharma, contributing to its successful $1 billion acquisition. CEO Stephen Hurly welcomed Powell, highlighting his expertise in driving growth initiatives crucial for LAVA's bispecific gamma delta T cell engagers pipeline, particularly LAVA-051 and LAVA-1207.
LAVA Therapeutics (Nasdaq: LVTX) has announced it will present clinical data for LAVA-051 during the Society for Immunotherapy of Cancer’s 37th Annual Meeting from November 8-12, 2022. The presentation will focus on the mechanism of action of LAVA-051, a bispecific gamma delta T cell engager, confirming pharmacodynamics in a clinical setting. Chief Medical Officer Benjamin Winograd will present the findings on November 11, 2022.
LAVA’s Gammabody™ platform aims to treat solid and hematological malignancies.
Seagen and LAVA Therapeutics have entered an exclusive license agreement for LAVA-1223, a bispecific T cell engager targeting EGFR-expressing solid tumors. LAVA will receive a $50 million upfront payment and could earn up to $650 million in potential milestones, plus royalties on future sales. This partnership allows Seagen to enhance its targeted cancer therapy portfolio while LAVA aims to validate its Gammabody™ platform. LAVA-1223 is designed to activate Vγ9Vδ2 T cells to improve immune response against tumors.
Seagen has entered an exclusive license agreement with LAVA Therapeutics to develop and commercialize LAVA-1223, a bispecific T cell engager targeting EGFR-expressing solid tumors. LAVA will receive an upfront payment of
LAVA Therapeutics N.V. (Nasdaq: LVTX) reported encouraging initial Phase 1/2a clinical findings for LAVA-051 targeting chronic lymphocytic leukemia and multiple myeloma, highlighting anti-tumor activity and safety. The company has a cash position of $110.7 million as of June 30, 2022, expected to fund operations for approximately two years. Ongoing trials for LAVA-1207 in metastatic castration-resistant prostate cancer are also progressing, with additional clinical data anticipated in Q4 2022.
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company, announced that its CEO Stephen Hurly will present at the H.C. Wainwright 24th Annual Global Investment Conference. The virtual presentation is scheduled for September 12, 2022, and will be available for on-demand viewing starting at 7:00 a.m. EDT. Investors can access the webcast through the investor relations section on LAVA Therapeutics' website, where a replay will be available for 90 days.
The company is focused on developing bispecific gamma delta T cell engagers through its proprietary Gammabody™ platform.
LAVA Therapeutics hosted a clinical update call on June 16, 2022, focusing on the promising Phase 1/2a clinical trial data of LAVA-051, a bispecific gamma delta T cell engager, for treating chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). Initial data presented at the 2022 ASCO and EHA meetings show early signs of anti-tumor activity and an appealing safety profile. The trial's primary objectives include evaluating safety and determining the recommended Phase 2 dose, with additional cohorts being enrolled in Europe and the U.S.
LAVA Therapeutics N.V. (Nasdaq: LVTX) announced the appointments of James Noble and Jay Backstrom, M.D. as non-executive directors on June 15, 2022. The appointments aim to enhance the company's clinical development and regulatory affairs expertise as it advances clinical trials for hematologic and metastatic prostate cancers. The company also announced the departure of three board members, including co-founder Erik van den Berg. Noble and Backstrom bring extensive leadership experience from other biopharmaceutical firms, potentially benefiting LAVA's ongoing Gammabody development.
LAVA Therapeutics, a clinical stage immuno-oncology company, announced that CEO Stephen Hurly will join a fireside chat at the Jefferies Healthcare Conference in New York on June 9, 2022, from 11:30 to 11:55 a.m. EDT. The discussion will focus on the company's proprietary Gammabody™ platform, designed to enhance cancer treatment through bispecific gamma delta T cell engagers. A live webcast of the event can be accessed on the investor relations section of LAVA's website, with a replay available for 90 days post-event.